Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 149 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Postmenopausal Bone Loss Clear all
Completed Phase 3 Interventional Results available

Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis

NCT04064411
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
abaloparatide, abaloparatide solid microstructured transdermal system
Combination Product
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
50 Years to 85 Years · Female only
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
77
States / cities
Birmingham, Alabama • Anchorage, Alaska • Glendale, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 24, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Results available

3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs

NCT00718861
View directory record Official record
Conditions
Post-menopausal Osteoporosis
Interventions
Placebo, Zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
65 Years and older · Female only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
10
States / cities
San Diego, California • Lakewood, Colorado • Gainesville, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Oct 24, 2026, 4:55 PM EDT
Completed No phase listed Observational

Bone Metabolism After Bariatric Surgery

NCT01824797
View directory record Official record
Conditions
Obesity, Osteoporosis
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
40 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 16, 2019 · Synced Oct 24, 2026, 4:55 PM EDT
Completed Not applicable Interventional Results available

Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer

NCT00436917
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
zoledronic acid, Letrozole as adjuvant therapy
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 24, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Results available

Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis

NCT03974100
View directory record Official record
Conditions
Postmenopausal Women With Osteoporosis
Interventions
GP2411, EU-Prolia (EU-authorized Prolia®)
Biological
Lead sponsor
Sandoz
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Peoria, Arizona • Miami, Florida • Wichita, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Oct 24, 2026, 4:55 PM EDT
Active, not recruiting Phase 2 Interventional

A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)

NCT06577935
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
AGA2118, Placebo
Drug · Other
Lead sponsor
Angitia Biopharmaceuticals
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Birmingham, Alabama • Gainesville, Georgia • Albuquerque, New Mexico + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 24, 2026, 4:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women

NCT01250145
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
LY333334, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Female only
Enrollment
251 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Daytona Beach, Florida • Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Oct 24, 2026, 4:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

DHEA Augmentation of Musculoskeletal Adaptations to Exercise in Older Women

NCT03227458
View directory record Official record
Conditions
Low Bone Mass, Osteoporosis, Postmenopausal
Interventions
DHEA, Placebo, Exercise
Other · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
55 Years to 85 Years · Female only
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 24, 2026, 4:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tart Cherry Supplementation and Women's Bone Health Study

NCT04167150
View directory record Official record
Conditions
Osteoporosis, Postmenopausal, Osteoporosis, Age-Related
Interventions
tart cherry juice concentrate is a commercial product provided by King Orchards (Central Lake, MI)
Dietary Supplement
Lead sponsor
Oklahoma State University
Other
Eligibility
65 Years to 80 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Stillwater, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 24, 2026, 4:55 PM EDT
Completed No phase listed Observational

Assessment of Cortical Bone Mechanics Technology (CBMT) Fracture Discrimination Capability

NCT05721898
View directory record Official record
Conditions
Osteoporosis, Osteopenia or Osteoporosis, Osteoporosis, Postmenopausal, Osteoporosis Risk, Osteoporotic Fractures, Fragility Fracture, Bone Fracture
Interventions
Cortical Bone Mechanics Technology
Diagnostic Test
Lead sponsor
Ohio University
Other
Eligibility
50 Years to 80 Years · Female only
Enrollment
394 participants
Timeline
2022 – 2023
U.S. locations
5
States / cities
Gainesville, Florida • Jacksonville, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 24, 2026, 4:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Role of T-cells in Post-Menopausal Osteoporosis

NCT00787904
View directory record Official record
Conditions
Osteoporosis
Interventions
Not listed
Lead sponsor
Atlanta VA Medical Center
Federal
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Oct 24, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Atenolol for the Prevention of Osteoporosis (APO)

NCT04905277
View directory record Official record
Conditions
Healthy
Interventions
Atenolol 50 MG, Placebo
Drug
Lead sponsor
Sundeep Khosla, M.D.
Other
Eligibility
50 Years to 75 Years · Female only
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
3
States / cities
Scarborough, Maine • Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 24, 2026, 4:55 PM EDT
Completed Phase 4 Interventional Results available

Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density

NCT00431444
View directory record Official record
Conditions
Osteoporosis
Interventions
Raloxifene, Zoledronic acid, Placebo oral pills, Placebo intravenous (i.v.) infusion
Drug
Lead sponsor
Novartis
Industry
Eligibility
45 Years to 80 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Phoenix, Arizona • Buena Park, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2011 · Synced Oct 24, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis

NCT01674621
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
Abaloparatide Transdermal (50 mcg), Abaloparatide Transdermal (100 mcg), Abaloparatide Transdermal (150 mcg), Abaloparatide Injection (80 mcg), Abaloparatide Placebo
Drug
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
Up to 85 Years · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Lakewood, Colorado • Atlanta, Georgia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 24, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Results available

DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis

NCT00048074
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
ibandronate [Bonviva/Boniva]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
1,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
19
States / cities
Little Rock, Arkansas • Irvine, California • Rancho Mirage, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 24, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Results available

Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older

NCT00132808
View directory record Official record
Conditions
Osteopenia
Interventions
Zoledronic Acid, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years and older · Female only
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 12, 2016 · Synced Oct 24, 2026, 4:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mediterranean Diet for Post-menopausal Women: Effects on Bone Turnover

NCT01653275
View directory record Official record
Conditions
Osteoporosis, Postmenopausal Bone Loss
Interventions
Mediterranean Diet
Other
Lead sponsor
UConn Health
Other
Eligibility
65 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 24, 2026, 4:55 PM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis

NCT00172107
View directory record Official record
Conditions
Osteoporosis
Interventions
ALX1-11 50 mcg, placebo, ALX1-11 75mcg, ALX1-11
Drug
Lead sponsor
Shire
Industry
Eligibility
50 Years to 75 Years · Female only
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 1997
U.S. locations
15
States / cities
Peoria, Arizona • Loma Linda, California • Mill Valley, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 24, 2026, 4:55 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Low-Dose Hormone Replacement Therapy and Alendronate for Osteoporosis

NCT00000430
View directory record Official record
Conditions
Osteopenia, Osteoporosis
Interventions
Alendronate, Estrogen/progestin therapy
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
60 Years and older · Female only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2004
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 4, 2007 · Synced Oct 24, 2026, 4:55 PM EDT
Completed Phase 3 Interventional

Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis

NCT00383422
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Arzoxifene, Raloxifene
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years to 75 Years · Female only
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Gainesville, Georgia • Urbandale, Iowa • Billings, Montana + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2010 · Synced Oct 24, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Results available

Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy

NCT00050011
View directory record Official record
Conditions
Breast Neoplasms, Osteoporosis
Interventions
Zoledronic Acid, Letrozole
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years · Female only
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
43
States / cities
Springdale, Arkansas • Burbank, California • Lafayette, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2014 · Synced Oct 24, 2026, 4:55 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

NCT04467983
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Denosumab Injection, Abaloparatide
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
45 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 24, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Combination Osteogenic Therapy in Established Osteoporosis

NCT00018447
View directory record Official record
Conditions
Osteoporosis, Post-Menopausal
Interventions
PTH 1-34, MFPSR-fluoride
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
60 Years to 80 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2003
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 24, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Results available

A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis

NCT00541658
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
50 Years and older · Female only
Enrollment
923 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
20
States / cities
Birmingham, Alabama • Oakland, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 24, 2026, 4:55 PM EDT